The isoflavone puerarin exerts anti-tumor activity in pancreatic ductal adenocarcinoma by suppressing mTOR-mediated glucose metabolism

• DOI: 10.18632/aging.203725
• Publication Date: 2021-12-04T22:38:05Z
• Authors: Hengyue Zhu; Yanyi Xiao; Hangcheng Guo; Yangyang Guo; Youze Huang; Yunfeng Shan; Yongheng Bai; Xiangyang Lin; Hong Lu
• Keywords: 0301 basic medicine; Mice, Inbred BALB C; TOR Serine-Threonine Kinases; Blotting, Western; Mice, Nude; Antineoplastic Agents; Apoptosis; Adenocarcinoma; Flow Cytometry; Isoflavones; 3. Good health; Molecular Docking Simulation; Pancreatic Neoplasms; Mice; 03 medical and health sciences; Glucose; Cell Movement; Cell Line, Tumor; Animals; Humans; Neoplasm Transplantation; Research Paper; Carcinoma, Pancreatic Ductal; Cell Proliferation

Puerarin (8-(β-D-glucopyranosyl)-4', 7-dihydroxyisoflavone), a natural flavonoid compound isolated from the traditional Chinese herb Radix puerariae, have been demonstrated has potential anti-tumor effects via induction of apoptosis and inhibition of proliferation. However, the effect and molecular mechanism of puerarin in pancreatic ductal adenocarcinoma (PDAC) remains unknown. In this study, the tumor-suppressive effects of puerarin were determined by both in-vitro and in-vivo assays. The effects of puerarin on the proliferation, apoptosis, migration and invasion of pancreatic cancer cells (PCCs), and tumor growth and metastasis in PDAC xenograft mouse model were performed. Puerarin treatment significantly repressed PCC proliferation. Puerarin induced the mitochondrial-dependent apoptosis of PCCs by causing a Bcl-2/Bax imbalance. Moreover, puerarin inhibited PCC migration and invasion by antagonizing epithelial-mesenchymal transition (EMT). In nude mouse model, PDAC growth and metastasis were reduced by puerarin administration. Mechanistically, puerarin exerted its therapeutic effects on PDAC by suppressing Akt/mTOR signaling. Importantly, puerarin bound to the kinase domain of mTOR protein, affecting the activity of the surrounding amino acid residues associated with the binding of the ATP-Mg2+ complex. Further studies showed that the inhibitory effects of puerarin on PCCs were abolished by a mTOR activator, indicating a crucial role of mTOR in anti-tumor effects of puerarin in PDAC. As a result, puerarin hindered glucose uptake and metabolism by downregulating the oxygen consumption rate (OCR) and the extracellular acidification rate (ECAR) dependent upon HIF-1α and glucose transporter GLUT1. Therefore, these findings indicated that puerarin has therapeutic potential for the treatment of PDAC by suppressing glucose uptake and metabolism via Akt/mTOR activity.